

**Biota Holdings Limited**

ACN 006 479 081

10/585 Blackburn Road  
Notting Hill VIC 3168  
Australia**T** +61 3 9915 3700**F** +61 3 9915 3702**E** [info@biota.com.au](mailto:info@biota.com.au)**W** [www.biota.com.au](http://www.biota.com.au)*For Immediate Release*

Melbourne, Australia — 27 October 2011

**Relenza September Quarterly Royalty**

Biota Holdings Limited (ASX:BTA) today advised that it had received written notification from GlaxoSmithKline (GSK) that, for the three months ended 30 September 2011, Relenza sales were \$3.3 million and indicative royalties were \$0.23 million. GSK advised that the figures were calculated on an Australian dollar exchange rate of 1.5952 A\$ to the UK pound.

Actual payment will be calculated on the exchange rate of 30 April 2012.

**About Biota**

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product Inavir<sup>®</sup>, is approved for marketing in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Relenza<sup>™</sup> is a registered trademark of the GlaxoSmithKline group of companies.

Inavir<sup>®</sup> is registered to Daiichi Sankyo.

**Investor / Analyst Enquiries**  
**Biota Holdings Limited**

Peter Cook

T: +61 3 9915 3720

Damian Lismore

T: +61 3 9915 3721

**Media Enquiries**

Tim Duncan, Hinton &amp; Associates

T: +61 3 9600 1979 / M: +61 408 441 122

**US Enquiries**

Hershel Berry, Blueprint Life Science Group

M: +1 415 505 3749